143 related articles for article (PubMed ID: 3629544)
1. Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia.
Regañón E; Vila V; Aznar J; Garrido G; Estellés A; Berenguer J
Thromb Res; 1987 Jun; 46(5):705-14. PubMed ID: 3629544
[TBL] [Abstract][Full Text] [Related]
2. Quantitative abnormality of an Aalpha chain molecular weight form in the fibrinogen of cirrhotic patients.
Weinstein MJ; Deykin D
Br J Haematol; 1978 Dec; 40(4):617-30. PubMed ID: 728374
[TBL] [Abstract][Full Text] [Related]
3. Measuring plasma fibrinogen levels in patients with liver cirrhosis. The occurrence of proteolytic fibrin(ogen) degradation products and their influence on several fibrinogen assays.
de Maat MP; Nieuwenhuizen W; Knot EA; van Buuren HR; Swart GR
Thromb Res; 1995 May; 78(4):353-62. PubMed ID: 7631315
[TBL] [Abstract][Full Text] [Related]
4. The importance of simple coagulation tests (fibrinogen assays and thrombin coagulase clotting time) in the diagnosis of liver cancer.
Pengo V; Levi Minzi S; Dal Bo Zanon R; Cappellato G; Farinati F; Girolami A
J Med; 1984; 15(2):149-60. PubMed ID: 6096471
[TBL] [Abstract][Full Text] [Related]
5. Investigations on intravascular coagulation in liver disease: souble fibrin monomer complexes in liver cirrhosis.
Coccheri S; Palareti G; Dalmonte PR; Poggi M; Boggian O
Haemostasis; 1979; 8(1):8-18. PubMed ID: 378778
[TBL] [Abstract][Full Text] [Related]
6. Fibrinogenolysis and fibrinolysis with strenuous exercise.
Ferguson EW; Barr CF; Bernier LL
J Appl Physiol Respir Environ Exerc Physiol; 1979 Dec; 47(6):1157-61. PubMed ID: 536284
[TBL] [Abstract][Full Text] [Related]
7. [Fibrinogen and fibrin structure in patients with cirrhosis of the liver (author's transl)].
Klingemann HG; Brunswig D; Liehr H
Z Gastroenterol; 1978 Sep; 16(9):564-73. PubMed ID: 706517
[TBL] [Abstract][Full Text] [Related]
8. Human fibrinogen heterogeneity. A study of limited fibrinogen degradation.
Regañón E; Vila V; Aznar J; Laiz B
Clin Chim Acta; 1989 Sep; 184(1):7-17. PubMed ID: 2532081
[TBL] [Abstract][Full Text] [Related]
9. Fibrin formation and lysis studies in dengue virus infection.
Marchi R; Nagaswami C; Weisel JW
Blood Coagul Fibrinolysis; 2009 Oct; 20(7):575-82. PubMed ID: 19644359
[TBL] [Abstract][Full Text] [Related]
10. Role of sialic acid in acquired dysfibrinogenemia associated with liver cirrhosis.
Narvaiza MJ; Fernández J; Cuesta B; Páramo JA; Rocha E
Ric Clin Lab; 1986; 16(4):563-8. PubMed ID: 3576054
[TBL] [Abstract][Full Text] [Related]
11. Fibrinogen Barcelona I. Congenital dysfibrinogenemia characterized by defective release of fibrinopeptide A and fibrinogen degradation products.
Vila V; Regañón E; Aznar J; Navarro G; Salas M
Thromb Res; 1987 Mar; 45(5):437-49. PubMed ID: 2954261
[TBL] [Abstract][Full Text] [Related]
12. Impaired fibrin formation in advanced cirrhosis.
Dettori AG; Ponari O; Civardi E; Megha A; Pini M; Poti R
Haemostasis; 1977; 6(2):137-48. PubMed ID: 863294
[TBL] [Abstract][Full Text] [Related]
13. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains.
Martinez J; MacDonald KA; Palascak JE
Blood; 1983 Jun; 61(6):1196-202. PubMed ID: 6839020
[TBL] [Abstract][Full Text] [Related]
14. Sialic acid in fibrinogen: effects of sialic acid on fibrinogen-fibrin conversion by thrombin and properties of asialofibrin clot.
Okude M; Yamanaka A; Morimoto Y; Akihama S
Biol Pharm Bull; 1993 May; 16(5):448-52. PubMed ID: 8364489
[TBL] [Abstract][Full Text] [Related]
15. Dysfibrinogenemia associated with liver disease.
Palascak JE; Martinez J
J Clin Invest; 1977 Jul; 60(1):89-95. PubMed ID: 874092
[TBL] [Abstract][Full Text] [Related]
16. [Differentiation of fibrinolysis and fibrinogenolysis by analysis of FDP fragments].
Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Nakahata T; Saitoh H
Rinsho Byori; 1992 Jul; 40(7):789-94. PubMed ID: 1507499
[TBL] [Abstract][Full Text] [Related]
17. Fibrinogen Vicenza and Genova II: two new cases of congenital dysfibrinogenemia with isolated defect of fibrin monomer polymerization and inhibitory activity on normal coagulation.
Rodeghiero F; Castaman GC; Dal Belin Peruffo A; Dini E; Galletti A; Barone E; Gastaldi G
Thromb Haemost; 1987 Jun; 57(3):252-8. PubMed ID: 2958952
[TBL] [Abstract][Full Text] [Related]
18. Defective alpha-polymerization in the conversion of fibrinogen Baltimore to fibrin.
Brown CH; Crowe MF
J Clin Invest; 1975 Jun; 55(6):1190-4. PubMed ID: 1133167
[TBL] [Abstract][Full Text] [Related]
19. Abnormal fibrinogen heterogeneity and fibrinolytic activity in advanced liver disease.
Lipinski B; Lipinska I; Nowak A; Gurewich V
J Lab Clin Med; 1977 Jul; 90(1):187-94. PubMed ID: 406338
[TBL] [Abstract][Full Text] [Related]
20. Fibrinogen Troyes--fibrinogen Metz. Two new cases of congenital dysfibrinogenemia.
Soria J; Soria C; Samama M; Poirot E; Kling C
Thromb Diath Haemorrh; 1972 Jul; 27(3):619-33. PubMed ID: 4662617
[No Abstract] [Full Text] [Related]
[Next] [New Search]
